01819nam 2200421z- 450 991026113210332120210211(CKB)4100000002484765(oapen)https://directory.doabooks.org/handle/20.500.12854/55224(oapen)doab55224(EXLCZ)99410000000248476520202102d2017 |y 0engurmn|---annantxtrdacontentcrdamediacrrdacarrierOncolytic Viruses - Genetically Engineering the Future of Cancer TherapyFrontiers Media SA20171 online resource (193 p.)Frontiers Research Topics2-88945-358-8 The ability to genetically engineer oncolytic viruses in order to minimize side effects and improve the selective targeting of tumor cells has opened up novel opportunities for treating cancer. Understanding the mechanisms involved and the complex interaction between the viruses and the immune system will undoubtedly help guide the development of new strategies. Theranostic biomarkers to monitor these therapies in clinical trials serve an important need in this innovative field and demand further research.Medicine and Nursingbicsscantitumor immunitycancer immunotherapygene expressiononcoimmunologyoncolytic virusestheranostic nanomedicinetransgenesMedicine and NursingBenjamin Gesundheitauth1278230Joshua P. RosenzweigauthBOOK9910261132103321Oncolytic Viruses - Genetically Engineering the Future of Cancer Therapy3034281UNINA